EP3990626A4 - Récepteur antigènique chimèrique ayant un domaine de costimulation 4-1bb - Google Patents

Récepteur antigènique chimèrique ayant un domaine de costimulation 4-1bb Download PDF

Info

Publication number: EP3990626A4
Authority: EP; European Patent Office
Prior art keywords: antigen receptor; chimeric antigen; costimulation domain; costimulation; domain
Prior art date: 2019-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP20831651.3A

Other languages

German (de)

English (en)

Other versions

EP3990626A1 (fr

Inventor

Byoung S. Kwon

Kwanghee Kim

Jiwon Chung

Young Gyoon CHANG

Bo-Rim YI

Jungyun Lee

Sae Rom Lee

Hyuntae SON

Hye Mi Lee

Eun Hye Yoo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eutilex Co Ltd

Original Assignee

Eutilex Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-06-27

Filing date

2020-06-26

Publication date

2023-09-20

2019-08-12 Priority claimed from PCT/KR2019/010244 external-priority patent/WO2020032784A1/fr

2020-06-26 Application filed by Eutilex Co Ltd filed Critical Eutilex Co Ltd

2022-05-04 Publication of EP3990626A1 publication Critical patent/EP3990626A1/fr

2023-09-20 Publication of EP3990626A4 publication Critical patent/EP3990626A4/fr

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Developmental Biology & Embryology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP20831651.3A 2019-06-27 2020-06-26 Récepteur antigènique chimèrique ayant un domaine de costimulation 4-1bb Pending EP3990626A4 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201962867503P	2019-06-27	2019-06-27
PCT/KR2019/010244 WO2020032784A1 (fr)	2018-08-10	2019-08-12	Liaison du récepteur antigénique chimérique à hla-dr, et cellule car-t
US16/715,462 US11013765B2 (en)	2018-08-10	2019-12-16	Chimeric antigen receptor that binds HLA-DR and CAR-T cell
US202062991493P	2020-03-18	2020-03-18
US202063004827P	2020-04-03	2020-04-03
US202063043237P	2020-06-24	2020-06-24
PCT/IB2020/056097 WO2020261231A1 (fr)	2019-06-27	2020-06-26	Récepteur antigènique chimèrique ayant un domaine de costimulation 4-1bb

Publications (2)

Publication Number	Publication Date
EP3990626A1 EP3990626A1 (fr)	2022-05-04
EP3990626A4 true EP3990626A4 (fr)	2023-09-20

Family

ID=74061779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP20831651.3A Pending EP3990626A4 (fr)	2019-06-27	2020-06-26	Récepteur antigènique chimèrique ayant un domaine de costimulation 4-1bb

Country Status (9)

Country	Link
EP (1)	EP3990626A4 (fr)
JP (2)	JP2022538425A (fr)
KR (1)	KR20220030248A (fr)
CN (2)	CN114080452B (fr)
AU (1)	AU2020307673A1 (fr)
BR (1)	BR112021026406A2 (fr)
CA (1)	CA3144875A1 (fr)
MX (1)	MX2021015967A (fr)
WO (1)	WO2020261231A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2021001672A (es) *	2018-08-10	2021-07-15	Eutilex Co Ltd	Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
SG11202111130SA (en)	2019-04-30	2021-11-29	Senti Biosciences Inc	Chimeric receptors and methods of use thereof
KR102671410B1 (ko) *	2021-03-03	2024-06-04	진화섭	RANK 리간드(RANK ligand)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2025103439A1 (fr) *	2023-11-16	2025-05-22	广州瑞风生物科技有限公司	Récepteur antigénique chimérique et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015069922A2 (fr) *	2013-11-06	2015-05-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps anti-alk, conjugues, et recepteurs antigeniques chimeriques, et leur utilisation
WO2015187528A1 (fr) *	2014-06-02	2015-12-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Récepteurs d'antigènes chimériques ciblant cd-19
WO2018156711A1 (fr) *	2017-02-22	2018-08-30	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Récepteurs antigéniques chimériques se liant à il13ra2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050113564A1 (en) *	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
JP4331227B2 (ja) *	2004-07-09	2009-09-16	中外製薬株式会社	抗グリピカン３抗体
AU2013204922B2 (en) *	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
US9790282B2 (en) *	2013-03-25	2017-10-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US10195272B2 (en) *	2015-03-02	2019-02-05	The Nemours Foundation	Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
CN107847601A (zh) *	2015-06-04	2018-03-27	南加利福尼亚大学	Lym‑1和lym‑2靶向的car细胞免疫疗法
CN114181960B (zh) *	2015-10-09	2024-08-23	美天施生物科技有限公司	嵌合抗原受体和使用方法
CN105906720A (zh) *	2016-05-16	2016-08-31	武汉汉密顿生物科技股份有限公司	靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
CN106279438B (zh) *	2016-08-24	2019-10-22	北京领柯生物科技有限公司	新型嵌合抗原受体及其用途
CN108165568B (zh) *	2016-12-07	2020-12-08	上海恒润达生生物科技有限公司	一种培养CD19CAR-iNKT细胞方法及用途
US11286306B2 (en) *	2016-12-09	2022-03-29	H. Lee Moffitt Cancer Center And Research Institute, Inc.	TLR9-binding chimeric antigen receptors
CA3048648A1 (fr) *	2017-01-10	2018-07-19	The General Hospital Corporation	Lymphocytes t exprimant un recepteur antigenique chimerique
KR102664453B1 (ko) *	2017-02-21	2024-05-10	주식회사 유틸렉스	Hla-dr car-t 조성물 및 그를 제조하고 사용하는 방법
CN108728459B (zh) *	2017-04-24	2023-08-04	上海恒润达生生物科技股份有限公司	靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途
WO2018236909A1 (fr) *	2017-06-20	2018-12-27	La Jolla Institute For Allergy And Immunology	Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation dans la modulation de réponses inflammatoires et le traitement de l'athérosclérose
EP3661964A1 (fr) *	2017-07-31	2020-06-10	Lentigen Technology, Inc.	Compositions et méthodes de traitement du cancer par immunothérapie anti-cd19/cd20
CN108715859B (zh) *	2018-05-31	2021-08-03	中国医学科学院血液病医院(中国医学科学院血液学研究所)	靶向cd22的嵌合抗原受体及其应用
US20230071098A1 (en) *	2018-07-17	2023-03-09	Noile-Immune Biotech, Inc.	Anti-gpc3 single-chain antibody-containing car

2020
- 2020-06-26 AU AU2020307673A patent/AU2020307673A1/en active Pending
- 2020-06-26 KR KR1020227001944A patent/KR20220030248A/ko not_active Ceased
- 2020-06-26 EP EP20831651.3A patent/EP3990626A4/fr active Pending
- 2020-06-26 BR BR112021026406A patent/BR112021026406A2/pt unknown
- 2020-06-26 CA CA3144875A patent/CA3144875A1/fr active Pending
- 2020-06-26 MX MX2021015967A patent/MX2021015967A/es unknown
- 2020-06-26 JP JP2021576820A patent/JP2022538425A/ja active Pending
- 2020-06-26 CN CN202080047355.XA patent/CN114080452B/zh active Active
- 2020-06-26 CN CN202411914064.2A patent/CN119955732A/zh active Pending
- 2020-06-26 WO PCT/IB2020/056097 patent/WO2020261231A1/fr not_active Ceased
2025
- 2025-05-02 JP JP2025076601A patent/JP2025118764A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015069922A2 (fr) *	2013-11-06	2015-05-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps anti-alk, conjugues, et recepteurs antigeniques chimeriques, et leur utilisation
WO2015187528A1 (fr) *	2014-06-02	2015-12-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Récepteurs d'antigènes chimériques ciblant cd-19
WO2018156711A1 (fr) *	2017-02-22	2018-08-30	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Récepteurs antigéniques chimériques se liant à il13ra2

Also Published As

Publication number	Publication date
CN119955732A (zh)	2025-05-09
JP2025118764A (ja)	2025-08-13
AU2020307673A1 (en)	2022-01-20
EP3990626A1 (fr)	2022-05-04
BR112021026406A2 (pt)	2022-04-12
CA3144875A1 (fr)	2020-12-30
KR20220030248A (ko)	2022-03-10
CN114080452A (zh)	2022-02-22
MX2021015967A (es)	2022-04-06
JP2022538425A (ja)	2022-09-02
CN114080452B (zh)	2025-06-03
WO2020261231A1 (fr)	2020-12-30

Publication	Publication Date	Title
IL276396A (en)	2020-09-30	Chimeric antigen receptors against CD70
EP3990626A4 (fr)	2023-09-20	Récepteur antigènique chimèrique ayant un domaine de costimulation 4-1bb
IL283828A (en)	2021-07-29	Mnd promoter chimeric antigen receptors
IL281428A (en)	2021-04-29	Chimeric antigen receptor
DK3844267T3 (da)	2025-09-22	Fremgangsmåder til fremstilling af kimære antigenreceptorudtrykkende celler
EP3134434A4 (fr)	2017-10-25	Récepteurs d'antigènes chimères kappa/lambda
DK3405481T3 (da)	2023-04-17	Kimære antigenreceptorer målrettet epidermal vækstfaktorreceptor variant iii
HUE047929T2 (hu)	2020-05-28	Kiméra antigén receptor
PT3575315T (pt)	2022-12-16	Recetores de antigénios quiméricos
IL276836A (en)	2020-10-29	Cd83-binding chimeric antigen receptors
PT3286223T (pt)	2024-03-22	Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
EP3568406A4 (fr)	2020-10-21	Lymphocytes t exprimant un récepteur antigénique chimérique
DK3806903T5 (da)	2024-08-19	Cd79a kimæriske antigenreceptorer
EP4034254A4 (fr)	2023-11-01	Récepteurs à domaine transmembranaire hétérologue
EP3737688A4 (fr)	2021-11-03	Cellules immunitaires exprimant un récepteur antigénique chimérique
EP3688143A4 (fr)	2021-09-22	Récepteur d'antigène chimérique spécifique à pd-1 en tant qu'immunothérapie
EP4007809A4 (fr)	2023-02-22	Cellules nk-92 modifiées par un récepteur antigénique chimérique anti-b7-h4
EP3909248A4 (fr)	2022-11-16	Schéma amélioré de génération de listes de modes les plus probables
EP4242309A4 (fr)	2025-01-01	Récepteur antigénique chimérique
EP4065606A4 (fr)	2023-08-02	Récepteur antigénique chimérique pour antigènes glucidiques
GB201807862D0 (en)	2018-06-27	Chimeric antigen receptor
EP4041257A4 (fr)	2024-01-17	Récepteurs antigéniques chimériques contre le cytomégalovirus humain
HK40122793A (zh)	2025-10-10	具有4-1bb共刺激结构域的嵌合抗原受体
HK40066497B (zh)	2025-08-29	具有4-1bb共刺激结构域的嵌合抗原受体
HK40066497A (zh)	2022-08-19	具有4-1bb共刺激结构域的嵌合抗原受体

Legal Events

Date	Code	Title	Description
2021-01-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-04-02	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-04-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-05-04	17P	Request for examination filed	Effective date: 20211221
2022-05-04	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-10-05	DAV	Request for validation of the european patent (deleted)
2022-10-05	DAX	Request for extension of the european patent (deleted)
2023-08-17	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0005078300 Ipc: C07K0014705000
2023-09-20	A4	Supplementary search report drawn up and despatched	Effective date: 20230823
2023-09-20	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20230817BHEP Ipc: A61P 35/00 20060101ALI20230817BHEP Ipc: A61K 35/17 20150101ALI20230817BHEP Ipc: C12N 5/0783 20100101ALI20230817BHEP Ipc: C07K 16/30 20060101ALI20230817BHEP Ipc: C07K 16/28 20060101ALI20230817BHEP Ipc: C07K 14/725 20060101ALI20230817BHEP Ipc: C07K 14/705 20060101AFI20230817BHEP